AbbVie (ABBV) Q3 FY25 earnings call

AbbVie delivered a strong Q3 FY25, exceeding revenue and EPS expectations, driven by robust performance from its growth platform, particularly Skyrizi, Rinvoq, and neuroscience. The company raised its full-year outlook for the third time, underscoring confidence in its diversified portfolio and pipeline. Despite ongoing Humira erosion and macro headwinds in aesthetics, AbbVie is strategically investing in R&D and external innovation to secure long-term growth beyond the current decade.